Drug interactions
Dacarbazine + Idecabtagene vicleucel
Severity: Major
Dacarbazine and Idecabtagene vicleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dacarbazine is a myelosuppressive agent. Given around the time of CAR T-cell therapy it may impair T-cell collection, expansion and persistence and adds to cytopenias and infection risk.
What this interaction means in plain words
Dacarbazine and Idecabtagene vicleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Dacarbazine belongs to Oncology; Idecabtagene vicleucel belongs to Oncology.
Why it happens
Additive immunosuppression and myelosuppression, with possible cytotoxic effects on CAR T cells.
What to do
Avoid dacarbazine before leukapheresis and after infusion unless part of a planned protocol. Monitor blood counts and infections closely.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dacarbazine and Idecabtagene vicleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Dacarbazine
Other interactions of Idecabtagene vicleucel
Frequently asked questions
Can I take Dacarbazine with Idecabtagene vicleucel?
MediHelp rates the interaction as major. Dacarbazine and Idecabtagene vicleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Dacarbazine is a myelosuppressive agent. Given around the time of CAR T-cell therapy it may impair T-cell collection, expansion and persistence and adds to cytopenias and infection risk.
How serious is the interaction between Dacarbazine and Idecabtagene vicleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid dacarbazine before leukapheresis and after infusion unless part of a planned protocol. Monitor blood counts and infections closely.
What other medicines interact with Dacarbazine?
MediHelp also lists interactions of Dacarbazine with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Belatacept. The full list is on the Dacarbazine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
